Lonza Group AG

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, DHR-PB has a market cap of 916.76B. Regarding current trading prices, LZAGF is priced at $699.91, while DHR-PB trades at $1,261.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas DHR-PB's P/E ratio is 146.01. In terms of profitability, LZAGF's ROE is +0.06%, compared to DHR-PB's ROE of +0.07%. Regarding short-term risk, LZAGF is more volatile compared to DHR-PB. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, TMO has a market cap of 152.15B. Regarding current trading prices, LZAGF is priced at $699.91, while TMO trades at $403.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas TMO's P/E ratio is 23.64. In terms of profitability, LZAGF's ROE is +0.06%, compared to TMO's ROE of +0.13%. Regarding short-term risk, LZAGF is more volatile compared to TMO. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, DHR has a market cap of 135.68B. Regarding current trading prices, LZAGF is priced at $699.91, while DHR trades at $189.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas DHR's P/E ratio is 36.74. In terms of profitability, LZAGF's ROE is +0.06%, compared to DHR's ROE of +0.07%. Regarding short-term risk, LZAGF is more volatile compared to DHR. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, LZAGY has a market cap of 50.75B. Regarding current trading prices, LZAGF is priced at $699.91, while LZAGY trades at $70.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas LZAGY's P/E ratio is 65.14. In terms of profitability, LZAGF's ROE is +0.06%, compared to LZAGY's ROE of +0.06%. Regarding short-term risk, LZAGF is more volatile compared to LZAGY. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, IDXX has a market cap of 39.54B. Regarding current trading prices, LZAGF is priced at $699.91, while IDXX trades at $491.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas IDXX's P/E ratio is 45.53. In terms of profitability, LZAGF's ROE is +0.06%, compared to IDXX's ROE of +0.57%. Regarding short-term risk, LZAGF is more volatile compared to IDXX. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, A has a market cap of 30.49B. Regarding current trading prices, LZAGF is priced at $699.91, while A trades at $106.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas A's P/E ratio is 24.48. In terms of profitability, LZAGF's ROE is +0.06%, compared to A's ROE of +0.21%. Regarding short-term risk, LZAGF is more volatile compared to A. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, IQV has a market cap of 25.76B. Regarding current trading prices, LZAGF is priced at $699.91, while IQV trades at $148.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas IQV's P/E ratio is 20.32. In terms of profitability, LZAGF's ROE is +0.06%, compared to IQV's ROE of +0.21%. Regarding short-term risk, LZAGF is more volatile compared to IQV. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, WUXAY has a market cap of 23.44B. Regarding current trading prices, LZAGF is priced at $699.91, while WUXAY trades at $7.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas WUXAY's P/E ratio is 14.39. In terms of profitability, LZAGF's ROE is +0.06%, compared to WUXAY's ROE of +0.19%. Regarding short-term risk, LZAGF is less volatile compared to WUXAY. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, MTD has a market cap of 22.46B. Regarding current trading prices, LZAGF is priced at $699.91, while MTD trades at $1,080.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas MTD's P/E ratio is 27.00. In terms of profitability, LZAGF's ROE is +0.06%, compared to MTD's ROE of +1.21%. Regarding short-term risk, LZAGF is more volatile compared to MTD. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, WUXIF has a market cap of 21.32B. Regarding current trading prices, LZAGF is priced at $699.91, while WUXIF trades at $7.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas WUXIF's P/E ratio is 13.85. In terms of profitability, LZAGF's ROE is +0.06%, compared to WUXIF's ROE of +0.19%. Regarding short-term risk, LZAGF is more volatile compared to WUXIF. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, NTRA has a market cap of 20.60B. Regarding current trading prices, LZAGF is priced at $699.91, while NTRA trades at $151.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas NTRA's P/E ratio is -98.67. In terms of profitability, LZAGF's ROE is +0.06%, compared to NTRA's ROE of -0.21%. Regarding short-term risk, LZAGF is less volatile compared to NTRA. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, WAT has a market cap of 20.47B. Regarding current trading prices, LZAGF is priced at $699.91, while WAT trades at $343.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas WAT's P/E ratio is 31.21. In terms of profitability, LZAGF's ROE is +0.06%, compared to WAT's ROE of +0.39%. Regarding short-term risk, LZAGF is more volatile compared to WAT. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, DGX has a market cap of 19.75B. Regarding current trading prices, LZAGF is priced at $699.91, while DGX trades at $176.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas DGX's P/E ratio is 22.37. In terms of profitability, LZAGF's ROE is +0.06%, compared to DGX's ROE of +0.13%. Regarding short-term risk, LZAGF is more volatile compared to DGX. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, BMXMF has a market cap of 15.21B. Regarding current trading prices, LZAGF is priced at $699.91, while BMXMF trades at $128.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas BMXMF's P/E ratio is 31.37. In terms of profitability, LZAGF's ROE is +0.06%, compared to BMXMF's ROE of +0.10%. Regarding short-term risk, LZAGF is less volatile compared to BMXMF. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, PKI has a market cap of 14.46B. Regarding current trading prices, LZAGF is priced at $699.91, while PKI trades at $115.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas PKI's P/E ratio is 41.45. In terms of profitability, LZAGF's ROE is +0.06%, compared to PKI's ROE of +0.08%. Regarding short-term risk, LZAGF is more volatile compared to PKI. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, ILMN has a market cap of 12.00B. Regarding current trading prices, LZAGF is priced at $699.91, while ILMN trades at $75.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas ILMN's P/E ratio is -9.86. In terms of profitability, LZAGF's ROE is +0.06%, compared to ILMN's ROE of -0.42%. Regarding short-term risk, LZAGF is less volatile compared to ILMN. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, ERFSF has a market cap of 11.43B. Regarding current trading prices, LZAGF is priced at $699.91, while ERFSF trades at $64.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas ERFSF's P/E ratio is 27.53. In terms of profitability, LZAGF's ROE is +0.06%, compared to ERFSF's ROE of +0.07%. Regarding short-term risk, LZAGF is less volatile compared to ERFSF. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, ICLR has a market cap of 10.82B. Regarding current trading prices, LZAGF is priced at $699.91, while ICLR trades at $133.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas ICLR's P/E ratio is 14.59. In terms of profitability, LZAGF's ROE is +0.06%, compared to ICLR's ROE of +0.08%. Regarding short-term risk, LZAGF is less volatile compared to ICLR. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, RVTY has a market cap of 10.76B. Regarding current trading prices, LZAGF is priced at $699.91, while RVTY trades at $91.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas RVTY's P/E ratio is 37.70. In terms of profitability, LZAGF's ROE is +0.06%, compared to RVTY's ROE of +0.04%. Regarding short-term risk, LZAGF is more volatile compared to RVTY. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, TEM has a market cap of 10.31B. Regarding current trading prices, LZAGF is priced at $699.91, while TEM trades at $61.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas TEM's P/E ratio is -11.89. In terms of profitability, LZAGF's ROE is +0.06%, compared to TEM's ROE of +21.50%. Regarding short-term risk, LZAGF is less volatile compared to TEM. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, EXAS has a market cap of 9.74B. Regarding current trading prices, LZAGF is priced at $699.91, while EXAS trades at $51.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas EXAS's P/E ratio is -9.34. In terms of profitability, LZAGF's ROE is +0.06%, compared to EXAS's ROE of -0.36%. Regarding short-term risk, LZAGF is more volatile compared to EXAS. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, QGEN has a market cap of 9.05B. Regarding current trading prices, LZAGF is priced at $699.91, while QGEN trades at $41.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas QGEN's P/E ratio is 110.14. In terms of profitability, LZAGF's ROE is +0.06%, compared to QGEN's ROE of +0.02%. Regarding short-term risk, LZAGF is more volatile compared to QGEN. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, MEDP has a market cap of 8.51B. Regarding current trading prices, LZAGF is priced at $699.91, while MEDP trades at $296.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas MEDP's P/E ratio is 22.58. In terms of profitability, LZAGF's ROE is +0.06%, compared to MEDP's ROE of +0.54%. Regarding short-term risk, LZAGF is more volatile compared to MEDP. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, SKHHY has a market cap of 7.70B. Regarding current trading prices, LZAGF is priced at $699.91, while SKHHY trades at $16.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas SKHHY's P/E ratio is 22.59. In terms of profitability, LZAGF's ROE is +0.06%, compared to SKHHY's ROE of +0.07%. Regarding short-term risk, LZAGF is less volatile compared to SKHHY. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, SKHCF has a market cap of 7.11B. Regarding current trading prices, LZAGF is priced at $699.91, while SKHCF trades at $14.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas SKHCF's P/E ratio is 20.56. In terms of profitability, LZAGF's ROE is +0.06%, compared to SKHCF's ROE of +0.05%. Regarding short-term risk, LZAGF is less volatile compared to SKHCF. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, CRL has a market cap of 6.82B. Regarding current trading prices, LZAGF is priced at $699.91, while CRL trades at $138.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas CRL's P/E ratio is 660.90. In terms of profitability, LZAGF's ROE is +0.06%, compared to CRL's ROE of +0.00%. Regarding short-term risk, LZAGF is more volatile compared to CRL. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, DSRLF has a market cap of 5.81B. Regarding current trading prices, LZAGF is priced at $699.91, while DSRLF trades at $107.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas DSRLF's P/E ratio is 28.35. In terms of profitability, LZAGF's ROE is +0.06%, compared to DSRLF's ROE of +0.09%. Regarding short-term risk, LZAGF is more volatile compared to DSRLF. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, GH has a market cap of 5.17B. Regarding current trading prices, LZAGF is priced at $699.91, while GH trades at $41.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas GH's P/E ratio is -12.31. In terms of profitability, LZAGF's ROE is +0.06%, compared to GH's ROE of +3.69%. Regarding short-term risk, LZAGF is less volatile compared to GH. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, HNGZY has a market cap of 4.48B. Regarding current trading prices, LZAGF is priced at $699.91, while HNGZY trades at $4.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas HNGZY's P/E ratio is 26.67. In terms of profitability, LZAGF's ROE is +0.06%, compared to HNGZY's ROE of +0.02%. Regarding short-term risk, LZAGF is more volatile compared to HNGZY. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, SYNH has a market cap of 4.46B. Regarding current trading prices, LZAGF is priced at $699.91, while SYNH trades at $42.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas SYNH's P/E ratio is 61.40. In terms of profitability, LZAGF's ROE is +0.06%, compared to SYNH's ROE of +0.08%. Regarding short-term risk, LZAGF is more volatile compared to SYNH. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, RDNT has a market cap of 4.13B. Regarding current trading prices, LZAGF is priced at $699.91, while RDNT trades at $55.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas RDNT's P/E ratio is 1393.50. In terms of profitability, LZAGF's ROE is +0.06%, compared to RDNT's ROE of +0.02%. Regarding short-term risk, LZAGF is more volatile compared to RDNT. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, SHC has a market cap of 3.35B. Regarding current trading prices, LZAGF is priced at $699.91, while SHC trades at $11.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas SHC's P/E ratio is 73.88. In terms of profitability, LZAGF's ROE is +0.06%, compared to SHC's ROE of +0.06%. Regarding short-term risk, LZAGF is more volatile compared to SHC. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, OLK has a market cap of 3.24B. Regarding current trading prices, LZAGF is priced at $699.91, while OLK trades at $26.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas OLK's P/E ratio is -96.59. In terms of profitability, LZAGF's ROE is +0.06%, compared to OLK's ROE of -0.07%. Regarding short-term risk, LZAGF is more volatile compared to OLK. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, TWST has a market cap of 1.85B. Regarding current trading prices, LZAGF is priced at $699.91, while TWST trades at $30.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas TWST's P/E ratio is -9.48. In terms of profitability, LZAGF's ROE is +0.06%, compared to TWST's ROE of -0.41%. Regarding short-term risk, LZAGF is less volatile compared to TWST. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, VIMGF has a market cap of 1.81B. Regarding current trading prices, LZAGF is priced at $699.91, while VIMGF trades at $3.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas VIMGF's P/E ratio is 70.00. In terms of profitability, LZAGF's ROE is +0.06%, compared to VIMGF's ROE of +0.03%. Regarding short-term risk, LZAGF is more volatile compared to VIMGF. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, VIVO has a market cap of 1.49B. Regarding current trading prices, LZAGF is priced at $699.91, while VIVO trades at $33.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas VIVO's P/E ratio is 21.09. In terms of profitability, LZAGF's ROE is +0.06%, compared to VIVO's ROE of +0.12%. Regarding short-term risk, LZAGF is more volatile compared to VIVO. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, NEOG has a market cap of 1.30B. Regarding current trading prices, LZAGF is priced at $699.91, while NEOG trades at $5.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas NEOG's P/E ratio is -2.68. In terms of profitability, LZAGF's ROE is +0.06%, compared to NEOG's ROE of -0.17%. Regarding short-term risk, LZAGF is less volatile compared to NEOG. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, GRAL has a market cap of 1.24B. Regarding current trading prices, LZAGF is priced at $699.91, while GRAL trades at $35.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas GRAL's P/E ratio is -0.55. In terms of profitability, LZAGF's ROE is +0.06%, compared to GRAL's ROE of -0.70%. Regarding short-term risk, LZAGF is less volatile compared to GRAL. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, OPK has a market cap of 983.39M. Regarding current trading prices, LZAGF is priced at $699.91, while OPK trades at $1.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas OPK's P/E ratio is -20.67. In terms of profitability, LZAGF's ROE is +0.06%, compared to OPK's ROE of -0.03%. Regarding short-term risk, LZAGF is less volatile compared to OPK. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, MRCHF has a market cap of 962.56M. Regarding current trading prices, LZAGF is priced at $699.91, while MRCHF trades at $16.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas MRCHF's P/E ratio is -99.65. In terms of profitability, LZAGF's ROE is +0.06%, compared to MRCHF's ROE of -0.04%. Regarding short-term risk, LZAGF is less volatile compared to MRCHF. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, CDNA has a market cap of 855.25M. Regarding current trading prices, LZAGF is priced at $699.91, while CDNA trades at $15.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas CDNA's P/E ratio is 13.71. In terms of profitability, LZAGF's ROE is +0.06%, compared to CDNA's ROE of +0.18%. Regarding short-term risk, LZAGF is less volatile compared to CDNA. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, FLGT has a market cap of 599.74M. Regarding current trading prices, LZAGF is priced at $699.91, while FLGT trades at $19.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas FLGT's P/E ratio is -14.81. In terms of profitability, LZAGF's ROE is +0.06%, compared to FLGT's ROE of -0.04%. Regarding short-term risk, LZAGF is less volatile compared to FLGT. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, GRALV has a market cap of 579.39M. Regarding current trading prices, LZAGF is priced at $699.91, while GRALV trades at $18.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas GRALV's P/E ratio is N/A. In terms of profitability, LZAGF's ROE is +0.06%, compared to GRALV's ROE of N/A. Regarding short-term risk, LZAGF is less volatile compared to GRALV. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, CSTL has a market cap of 484.62M. Regarding current trading prices, LZAGF is priced at $699.91, while CSTL trades at $16.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas CSTL's P/E ratio is -88.34. In terms of profitability, LZAGF's ROE is +0.06%, compared to CSTL's ROE of -0.01%. Regarding short-term risk, LZAGF is more volatile compared to CSTL. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, PSNL has a market cap of 445.16M. Regarding current trading prices, LZAGF is priced at $699.91, while PSNL trades at $5.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas PSNL's P/E ratio is -3.68. In terms of profitability, LZAGF's ROE is +0.06%, compared to PSNL's ROE of -0.54%. Regarding short-term risk, LZAGF is less volatile compared to PSNL. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, LAB has a market cap of 406.41M. Regarding current trading prices, LZAGF is priced at $699.91, while LAB trades at $1.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas LAB's P/E ratio is -2.06. In terms of profitability, LZAGF's ROE is +0.06%, compared to LAB's ROE of -0.27%. Regarding short-term risk, LZAGF is less volatile compared to LAB. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, CO has a market cap of 400.08M. Regarding current trading prices, LZAGF is priced at $699.91, while CO trades at $2.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas CO's P/E ratio is 5.06. In terms of profitability, LZAGF's ROE is +0.06%, compared to CO's ROE of +0.18%. Regarding short-term risk, LZAGF is less volatile compared to CO. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, MYGN has a market cap of 358.55M. Regarding current trading prices, LZAGF is priced at $699.91, while MYGN trades at $3.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas MYGN's P/E ratio is -2.76. In terms of profitability, LZAGF's ROE is +0.06%, compared to MYGN's ROE of -0.15%. Regarding short-term risk, LZAGF is less volatile compared to MYGN. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, FLDM has a market cap of 294.19M. Regarding current trading prices, LZAGF is priced at $699.91, while FLDM trades at $3.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas FLDM's P/E ratio is -4.74. In terms of profitability, LZAGF's ROE is +0.06%, compared to FLDM's ROE of -0.27%. Regarding short-term risk, LZAGF is less volatile compared to FLDM. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, STIM has a market cap of 291.58M. Regarding current trading prices, LZAGF is priced at $699.91, while STIM trades at $4.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas STIM's P/E ratio is -3.21. In terms of profitability, LZAGF's ROE is +0.06%, compared to STIM's ROE of -2.04%. Regarding short-term risk, LZAGF is less volatile compared to STIM. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, NEO has a market cap of 207.17M. Regarding current trading prices, LZAGF is priced at $699.91, while NEO trades at $8.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas NEO's P/E ratio is -13.20. In terms of profitability, LZAGF's ROE is +0.06%, compared to NEO's ROE of -0.09%. Regarding short-term risk, LZAGF is more volatile compared to NEO. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, IDGXF has a market cap of 187.19M. Regarding current trading prices, LZAGF is priced at $699.91, while IDGXF trades at $0.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas IDGXF's P/E ratio is 8.05. In terms of profitability, LZAGF's ROE is +0.06%, compared to IDGXF's ROE of +0.24%. Regarding short-term risk, LZAGF is less volatile compared to IDGXF. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, ATLN has a market cap of 186.62M. Regarding current trading prices, LZAGF is priced at $699.91, while ATLN trades at $2.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas ATLN's P/E ratio is -0.81. In terms of profitability, LZAGF's ROE is +0.06%, compared to ATLN's ROE of -19.68%. Regarding short-term risk, LZAGF is less volatile compared to ATLN. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, EDTXF has a market cap of 177.44M. Regarding current trading prices, LZAGF is priced at $699.91, while EDTXF trades at $0.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas EDTXF's P/E ratio is -15.56. In terms of profitability, LZAGF's ROE is +0.06%, compared to EDTXF's ROE of +0.61%. Regarding short-term risk, LZAGF is more volatile compared to EDTXF. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, AMCY has a market cap of 171.27M. Regarding current trading prices, LZAGF is priced at $699.91, while AMCY trades at $3.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas AMCY's P/E ratio is N/A. In terms of profitability, LZAGF's ROE is +0.06%, compared to AMCY's ROE of N/A. Regarding short-term risk, LZAGF is more volatile compared to AMCY. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, NNGRF has a market cap of 164.30M. Regarding current trading prices, LZAGF is priced at $699.91, while NNGRF trades at $12.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas NNGRF's P/E ratio is 60.75. In terms of profitability, LZAGF's ROE is +0.06%, compared to NNGRF's ROE of -0.07%. Regarding short-term risk, LZAGF is more volatile compared to NNGRF. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, CORBF has a market cap of 145.97M. Regarding current trading prices, LZAGF is priced at $699.91, while CORBF trades at $1.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas CORBF's P/E ratio is 3.03. In terms of profitability, LZAGF's ROE is +0.06%, compared to CORBF's ROE of +0.11%. Regarding short-term risk, LZAGF is more volatile compared to CORBF. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, ACRS has a market cap of 136.43M. Regarding current trading prices, LZAGF is priced at $699.91, while ACRS trades at $1.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas ACRS's P/E ratio is -0.74. In terms of profitability, LZAGF's ROE is +0.06%, compared to ACRS's ROE of -0.94%. Regarding short-term risk, LZAGF is less volatile compared to ACRS. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, THOXF has a market cap of 130.94M. Regarding current trading prices, LZAGF is priced at $699.91, while THOXF trades at $0.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas THOXF's P/E ratio is -14.40. In terms of profitability, LZAGF's ROE is +0.06%, compared to THOXF's ROE of -0.91%. Regarding short-term risk, LZAGF is less volatile compared to THOXF. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, GTH has a market cap of 127.29M. Regarding current trading prices, LZAGF is priced at $699.91, while GTH trades at $4.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas GTH's P/E ratio is -1.11. In terms of profitability, LZAGF's ROE is +0.06%, compared to GTH's ROE of +0.00%. Regarding short-term risk, LZAGF is more volatile compared to GTH. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, DIUXF has a market cap of 115.49M. Regarding current trading prices, LZAGF is priced at $699.91, while DIUXF trades at $1.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas DIUXF's P/E ratio is 136.72. In terms of profitability, LZAGF's ROE is +0.06%, compared to DIUXF's ROE of -0.07%. Regarding short-term risk, LZAGF is more volatile compared to DIUXF. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, GENE has a market cap of 111.24M. Regarding current trading prices, LZAGF is priced at $699.91, while GENE trades at $0.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas GENE's P/E ratio is -38.25. In terms of profitability, LZAGF's ROE is +0.06%, compared to GENE's ROE of -3.62%. Regarding short-term risk, LZAGF is more volatile compared to GENE. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, XGN has a market cap of 102.79M. Regarding current trading prices, LZAGF is priced at $699.91, while XGN trades at $5.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas XGN's P/E ratio is -6.80. In terms of profitability, LZAGF's ROE is +0.06%, compared to XGN's ROE of -1.34%. Regarding short-term risk, LZAGF is less volatile compared to XGN. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, ANPCF has a market cap of 99.98M. Regarding current trading prices, LZAGF is priced at $699.91, while ANPCF trades at $0.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas ANPCF's P/E ratio is -3.10. In terms of profitability, LZAGF's ROE is +0.06%, compared to ANPCF's ROE of -0.54%. Regarding short-term risk, LZAGF is less volatile compared to ANPCF. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, MDXH has a market cap of 92.56M. Regarding current trading prices, LZAGF is priced at $699.91, while MDXH trades at $1.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas MDXH's P/E ratio is -1.61. In terms of profitability, LZAGF's ROE is +0.06%, compared to MDXH's ROE of -6.91%. Regarding short-term risk, LZAGF is less volatile compared to MDXH. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, SERA has a market cap of 81.48M. Regarding current trading prices, LZAGF is priced at $699.91, while SERA trades at $2.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas SERA's P/E ratio is -2.24. In terms of profitability, LZAGF's ROE is +0.06%, compared to SERA's ROE of -0.58%. Regarding short-term risk, LZAGF is less volatile compared to SERA. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, TIHE has a market cap of 71.85M. Regarding current trading prices, LZAGF is priced at $699.91, while TIHE trades at $1.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas TIHE's P/E ratio is 0.32. In terms of profitability, LZAGF's ROE is +0.06%, compared to TIHE's ROE of +0.01%. Regarding short-term risk, LZAGF is more volatile compared to TIHE. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, PRE has a market cap of 70.22M. Regarding current trading prices, LZAGF is priced at $699.91, while PRE trades at $5.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas PRE's P/E ratio is -1.45. In terms of profitability, LZAGF's ROE is +0.06%, compared to PRE's ROE of -0.25%. Regarding short-term risk, LZAGF is less volatile compared to PRE. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, PRENW has a market cap of 67.78M. Regarding current trading prices, LZAGF is priced at $699.91, while PRENW trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas PRENW's P/E ratio is N/A. In terms of profitability, LZAGF's ROE is +0.06%, compared to PRENW's ROE of -0.25%. Regarding short-term risk, LZAGF is more volatile compared to PRENW. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, NOTV has a market cap of 66.38M. Regarding current trading prices, LZAGF is priced at $699.91, while NOTV trades at $1.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas NOTV's P/E ratio is -0.43. In terms of profitability, LZAGF's ROE is +0.06%, compared to NOTV's ROE of -0.66%. Regarding short-term risk, LZAGF is less volatile compared to NOTV. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, BIOGF has a market cap of 65.41M. Regarding current trading prices, LZAGF is priced at $699.91, while BIOGF trades at $0.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas BIOGF's P/E ratio is -0.67. In terms of profitability, LZAGF's ROE is +0.06%, compared to BIOGF's ROE of +2.04%. Regarding short-term risk, LZAGF is more volatile compared to BIOGF. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, PCNEF has a market cap of 63.00M. Regarding current trading prices, LZAGF is priced at $699.91, while PCNEF trades at $2.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas PCNEF's P/E ratio is -8.44. In terms of profitability, LZAGF's ROE is +0.06%, compared to PCNEF's ROE of -0.21%. Regarding short-term risk, LZAGF is more volatile compared to PCNEF. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, BDSX has a market cap of 54.42M. Regarding current trading prices, LZAGF is priced at $699.91, while BDSX trades at $0.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas BDSX's P/E ratio is -1.13. In terms of profitability, LZAGF's ROE is +0.06%, compared to BDSX's ROE of -2.16%. Regarding short-term risk, LZAGF is less volatile compared to BDSX. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, PFGTF has a market cap of 50.58M. Regarding current trading prices, LZAGF is priced at $699.91, while PFGTF trades at $0.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas PFGTF's P/E ratio is -3.11. In terms of profitability, LZAGF's ROE is +0.06%, compared to PFGTF's ROE of -0.41%. Regarding short-term risk, LZAGF is less volatile compared to PFGTF. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, VNRX has a market cap of 50.19M. Regarding current trading prices, LZAGF is priced at $699.91, while VNRX trades at $0.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas VNRX's P/E ratio is -1.61. In terms of profitability, LZAGF's ROE is +0.06%, compared to VNRX's ROE of +1.29%. Regarding short-term risk, LZAGF is less volatile compared to VNRX. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, OPGN has a market cap of 49.43M. Regarding current trading prices, LZAGF is priced at $699.91, while OPGN trades at $4.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas OPGN's P/E ratio is -0.32. In terms of profitability, LZAGF's ROE is +0.06%, compared to OPGN's ROE of +1.20%. Regarding short-term risk, LZAGF is less volatile compared to OPGN. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, BIOQ has a market cap of 44.69M. Regarding current trading prices, LZAGF is priced at $699.91, while BIOQ trades at $50.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas BIOQ's P/E ratio is 14.41. In terms of profitability, LZAGF's ROE is +0.06%, compared to BIOQ's ROE of -0.06%. Regarding short-term risk, LZAGF is less volatile compared to BIOQ. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, DRIO has a market cap of 31.17M. Regarding current trading prices, LZAGF is priced at $699.91, while DRIO trades at $0.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas DRIO's P/E ratio is -1.23. In terms of profitability, LZAGF's ROE is +0.06%, compared to DRIO's ROE of -0.47%. Regarding short-term risk, LZAGF is less volatile compared to DRIO. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, STRRP has a market cap of 29.70M. Regarding current trading prices, LZAGF is priced at $699.91, while STRRP trades at $9.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas STRRP's P/E ratio is -4.64. In terms of profitability, LZAGF's ROE is +0.06%, compared to STRRP's ROE of -0.18%. Regarding short-term risk, LZAGF is more volatile compared to STRRP. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, CLIFF has a market cap of 29.65M. Regarding current trading prices, LZAGF is priced at $699.91, while CLIFF trades at $0.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas CLIFF's P/E ratio is -1.93. In terms of profitability, LZAGF's ROE is +0.06%, compared to CLIFF's ROE of -0.08%. Regarding short-term risk, LZAGF is less volatile compared to CLIFF. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, ANPCY has a market cap of 27.08M. Regarding current trading prices, LZAGF is priced at $699.91, while ANPCY trades at $0.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas ANPCY's P/E ratio is -0.92. In terms of profitability, LZAGF's ROE is +0.06%, compared to ANPCY's ROE of -0.75%. Regarding short-term risk, LZAGF is more volatile compared to ANPCY. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, AKU has a market cap of 26.27M. Regarding current trading prices, LZAGF is priced at $699.91, while AKU trades at $0.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas AKU's P/E ratio is -0.13. In terms of profitability, LZAGF's ROE is +0.06%, compared to AKU's ROE of -5.32%. Regarding short-term risk, LZAGF is less volatile compared to AKU. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, SNANF has a market cap of 23.89M. Regarding current trading prices, LZAGF is priced at $699.91, while SNANF trades at $0.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas SNANF's P/E ratio is -11.02. In terms of profitability, LZAGF's ROE is +0.06%, compared to SNANF's ROE of -2.51%. Regarding short-term risk, LZAGF is more volatile compared to SNANF. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, PMSNF has a market cap of 23.61M. Regarding current trading prices, LZAGF is priced at $699.91, while PMSNF trades at $0.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas PMSNF's P/E ratio is -4.00. In terms of profitability, LZAGF's ROE is +0.06%, compared to PMSNF's ROE of +0.69%. Regarding short-term risk, LZAGF is less volatile compared to PMSNF. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, VILGF has a market cap of 20.67M. Regarding current trading prices, LZAGF is priced at $699.91, while VILGF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas VILGF's P/E ratio is -0.30. In terms of profitability, LZAGF's ROE is +0.06%, compared to VILGF's ROE of N/A. Regarding short-term risk, LZAGF is more volatile compared to VILGF. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, ADVB has a market cap of 20.61M. Regarding current trading prices, LZAGF is priced at $699.91, while ADVB trades at $0.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas ADVB's P/E ratio is -6.80. In terms of profitability, LZAGF's ROE is +0.06%, compared to ADVB's ROE of -2.41%. Regarding short-term risk, LZAGF is less volatile compared to ADVB. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, IMMVF has a market cap of 19.33M. Regarding current trading prices, LZAGF is priced at $699.91, while IMMVF trades at $0.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas IMMVF's P/E ratio is -0.32. In terms of profitability, LZAGF's ROE is +0.06%, compared to IMMVF's ROE of -2.69%. Regarding short-term risk, LZAGF is less volatile compared to IMMVF. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, LDXHF has a market cap of 19.09M. Regarding current trading prices, LZAGF is priced at $699.91, while LDXHF trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas LDXHF's P/E ratio is -2.55. In terms of profitability, LZAGF's ROE is +0.06%, compared to LDXHF's ROE of -1.38%. Regarding short-term risk, LZAGF is less volatile compared to LDXHF. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, PCHM has a market cap of 17.38M. Regarding current trading prices, LZAGF is priced at $699.91, while PCHM trades at $2.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas PCHM's P/E ratio is -0.02. In terms of profitability, LZAGF's ROE is +0.06%, compared to PCHM's ROE of +0.53%. Regarding short-term risk, LZAGF is more volatile compared to PCHM. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, CEMI has a market cap of 16.71M. Regarding current trading prices, LZAGF is priced at $699.91, while CEMI trades at $0.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas CEMI's P/E ratio is -0.63. In terms of profitability, LZAGF's ROE is +0.06%, compared to CEMI's ROE of -0.89%. Regarding short-term risk, LZAGF is more volatile compared to CEMI. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, ENZ has a market cap of 16.44M. Regarding current trading prices, LZAGF is priced at $699.91, while ENZ trades at $0.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas ENZ's P/E ratio is -2.24. In terms of profitability, LZAGF's ROE is +0.06%, compared to ENZ's ROE of -0.39%. Regarding short-term risk, LZAGF is less volatile compared to ENZ. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, PMD has a market cap of 15.74M. Regarding current trading prices, LZAGF is priced at $699.91, while PMD trades at $2.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas PMD's P/E ratio is -5.24. In terms of profitability, LZAGF's ROE is +0.06%, compared to PMD's ROE of -0.33%. Regarding short-term risk, LZAGF is more volatile compared to PMD. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, BMKDF has a market cap of 15.45M. Regarding current trading prices, LZAGF is priced at $699.91, while BMKDF trades at $0.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas BMKDF's P/E ratio is -17.00. In terms of profitability, LZAGF's ROE is +0.06%, compared to BMKDF's ROE of +2.24%. Regarding short-term risk, LZAGF is less volatile compared to BMKDF. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, ABDXF has a market cap of 13.55M. Regarding current trading prices, LZAGF is priced at $699.91, while ABDXF trades at $0.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas ABDXF's P/E ratio is -1.40. In terms of profitability, LZAGF's ROE is +0.06%, compared to ABDXF's ROE of -0.63%. Regarding short-term risk, LZAGF is more volatile compared to ABDXF. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, ME has a market cap of 13.34M. Regarding current trading prices, LZAGF is priced at $699.91, while ME trades at $0.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas ME's P/E ratio is -0.03. In terms of profitability, LZAGF's ROE is +0.06%, compared to ME's ROE of -3.04%. Regarding short-term risk, LZAGF is less volatile compared to ME. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, BNGO has a market cap of 11.90M. Regarding current trading prices, LZAGF is priced at $699.91, while BNGO trades at $3.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas BNGO's P/E ratio is -0.04. In terms of profitability, LZAGF's ROE is +0.06%, compared to BNGO's ROE of -1.81%. Regarding short-term risk, LZAGF is more volatile compared to BNGO. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, IZOZF has a market cap of 11.50M. Regarding current trading prices, LZAGF is priced at $699.91, while IZOZF trades at $0.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas IZOZF's P/E ratio is -6.33. In terms of profitability, LZAGF's ROE is +0.06%, compared to IZOZF's ROE of +0.47%. Regarding short-term risk, LZAGF is more volatile compared to IZOZF. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, PRPO has a market cap of 10.02M. Regarding current trading prices, LZAGF is priced at $699.91, while PRPO trades at $6.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas PRPO's P/E ratio is -2.26. In terms of profitability, LZAGF's ROE is +0.06%, compared to PRPO's ROE of -0.35%. Regarding short-term risk, LZAGF is more volatile compared to PRPO. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, CNTG has a market cap of 9.43M. Regarding current trading prices, LZAGF is priced at $699.91, while CNTG trades at $0.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas CNTG's P/E ratio is -0.23. In terms of profitability, LZAGF's ROE is +0.06%, compared to CNTG's ROE of +3.98%. Regarding short-term risk, LZAGF is less volatile compared to CNTG. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, MXDHF has a market cap of 8.65M. Regarding current trading prices, LZAGF is priced at $699.91, while MXDHF trades at $0.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas MXDHF's P/E ratio is -0.12. In terms of profitability, LZAGF's ROE is +0.06%, compared to MXDHF's ROE of -6.91%. Regarding short-term risk, LZAGF is more volatile compared to MXDHF. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, INBS has a market cap of 8.24M. Regarding current trading prices, LZAGF is priced at $699.91, while INBS trades at $1.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas INBS's P/E ratio is 10.08. In terms of profitability, LZAGF's ROE is +0.06%, compared to INBS's ROE of -1.43%. Regarding short-term risk, LZAGF is less volatile compared to INBS. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, STRR has a market cap of 7.98M. Regarding current trading prices, LZAGF is priced at $699.91, while STRR trades at $2.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas STRR's P/E ratio is -0.75. In terms of profitability, LZAGF's ROE is +0.06%, compared to STRR's ROE of -0.18%. Regarding short-term risk, LZAGF is less volatile compared to STRR. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, MYNZ has a market cap of 7.45M. Regarding current trading prices, LZAGF is priced at $699.91, while MYNZ trades at $2.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas MYNZ's P/E ratio is -0.11. In terms of profitability, LZAGF's ROE is +0.06%, compared to MYNZ's ROE of -16.99%. Regarding short-term risk, LZAGF is less volatile compared to MYNZ. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, VRCDF has a market cap of 7.28M. Regarding current trading prices, LZAGF is priced at $699.91, while VRCDF trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas VRCDF's P/E ratio is -1.00. In terms of profitability, LZAGF's ROE is +0.06%, compared to VRCDF's ROE of -0.73%. Regarding short-term risk, LZAGF is less volatile compared to VRCDF. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, TDSGF has a market cap of 7.13M. Regarding current trading prices, LZAGF is priced at $699.91, while TDSGF trades at $0.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas TDSGF's P/E ratio is -2.38. In terms of profitability, LZAGF's ROE is +0.06%, compared to TDSGF's ROE of -3.19%. Regarding short-term risk, LZAGF is more volatile compared to TDSGF. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, GNTLF has a market cap of 6.07M. Regarding current trading prices, LZAGF is priced at $699.91, while GNTLF trades at $1.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas GNTLF's P/E ratio is -16.67. In terms of profitability, LZAGF's ROE is +0.06%, compared to GNTLF's ROE of -3.62%. Regarding short-term risk, LZAGF is more volatile compared to GNTLF. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, SQIDF has a market cap of 6.07M. Regarding current trading prices, LZAGF is priced at $699.91, while SQIDF trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas SQIDF's P/E ratio is -0.37. In terms of profitability, LZAGF's ROE is +0.06%, compared to SQIDF's ROE of +0.00%. Regarding short-term risk, LZAGF is less volatile compared to SQIDF. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, NVTA has a market cap of 5.44M. Regarding current trading prices, LZAGF is priced at $699.91, while NVTA trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas NVTA's P/E ratio is -0.00. In terms of profitability, LZAGF's ROE is +0.06%, compared to NVTA's ROE of +1.79%. Regarding short-term risk, LZAGF is less volatile compared to NVTA. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, APDN has a market cap of 5.33M. Regarding current trading prices, LZAGF is priced at $699.91, while APDN trades at $0.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas APDN's P/E ratio is -0.03. In terms of profitability, LZAGF's ROE is +0.06%, compared to APDN's ROE of -1.00%. Regarding short-term risk, LZAGF is less volatile compared to APDN. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, LMDXW has a market cap of 5.10M. Regarding current trading prices, LZAGF is priced at $699.91, while LMDXW trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas LMDXW's P/E ratio is -0.00. In terms of profitability, LZAGF's ROE is +0.06%, compared to LMDXW's ROE of -15.58%. Regarding short-term risk, LZAGF is less volatile compared to LMDXW. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, LMDX has a market cap of 5.10M. Regarding current trading prices, LZAGF is priced at $699.91, while LMDX trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas LMDX's P/E ratio is -0.01. In terms of profitability, LZAGF's ROE is +0.06%, compared to LMDX's ROE of -15.58%. Regarding short-term risk, LZAGF is less volatile compared to LMDX. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, BGLC has a market cap of 4.80M. Regarding current trading prices, LZAGF is priced at $699.91, while BGLC trades at $2.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas BGLC's P/E ratio is -2.97. In terms of profitability, LZAGF's ROE is +0.06%, compared to BGLC's ROE of -0.17%. Regarding short-term risk, LZAGF is less volatile compared to BGLC. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, SLDX has a market cap of 4.78M. Regarding current trading prices, LZAGF is priced at $699.91, while SLDX trades at $0.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas SLDX's P/E ratio is -0.01. In terms of profitability, LZAGF's ROE is +0.06%, compared to SLDX's ROE of +0.06%. Regarding short-term risk, LZAGF is less volatile compared to SLDX. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, CHEK has a market cap of 4.75M. Regarding current trading prices, LZAGF is priced at $699.91, while CHEK trades at $0.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas CHEK's P/E ratio is -0.38. In terms of profitability, LZAGF's ROE is +0.06%, compared to CHEK's ROE of -0.52%. Regarding short-term risk, LZAGF is less volatile compared to CHEK. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, RNVA has a market cap of 4.31M. Regarding current trading prices, LZAGF is priced at $699.91, while RNVA trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas RNVA's P/E ratio is N/A. In terms of profitability, LZAGF's ROE is +0.06%, compared to RNVA's ROE of +0.23%. Regarding short-term risk, LZAGF is more volatile compared to RNVA. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, JMPHF has a market cap of 4.18M. Regarding current trading prices, LZAGF is priced at $699.91, while JMPHF trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas JMPHF's P/E ratio is -0.91. In terms of profitability, LZAGF's ROE is +0.06%, compared to JMPHF's ROE of -0.11%. Regarding short-term risk, LZAGF is less volatile compared to JMPHF. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, TTOO has a market cap of 4.14M. Regarding current trading prices, LZAGF is priced at $699.91, while TTOO trades at $0.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas TTOO's P/E ratio is -4.92. In terms of profitability, LZAGF's ROE is +0.06%, compared to TTOO's ROE of +2.06%. Regarding short-term risk, LZAGF is less volatile compared to TTOO. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, BIAF has a market cap of 3.76M. Regarding current trading prices, LZAGF is priced at $699.91, while BIAF trades at $0.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas BIAF's P/E ratio is -0.27. In terms of profitability, LZAGF's ROE is +0.06%, compared to BIAF's ROE of -2.51%. Regarding short-term risk, LZAGF is less volatile compared to BIAF. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, BIAFW has a market cap of 3.65M. Regarding current trading prices, LZAGF is priced at $699.91, while BIAFW trades at $0.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas BIAFW's P/E ratio is N/A. In terms of profitability, LZAGF's ROE is +0.06%, compared to BIAFW's ROE of -2.51%. Regarding short-term risk, LZAGF is more volatile compared to BIAFW. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, SZLSF has a market cap of 3.57M. Regarding current trading prices, LZAGF is priced at $699.91, while SZLSF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas SZLSF's P/E ratio is -0.02. In terms of profitability, LZAGF's ROE is +0.06%, compared to SZLSF's ROE of +0.13%. Regarding short-term risk, LZAGF is less volatile compared to SZLSF. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, IDXG has a market cap of 3.36M. Regarding current trading prices, LZAGF is priced at $699.91, while IDXG trades at $0.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas IDXG's P/E ratio is 1.85. In terms of profitability, LZAGF's ROE is +0.06%, compared to IDXG's ROE of -0.66%. Regarding short-term risk, LZAGF is less volatile compared to IDXG. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, DMTK has a market cap of 3.29M. Regarding current trading prices, LZAGF is priced at $699.91, while DMTK trades at $0.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas DMTK's P/E ratio is -0.04. In terms of profitability, LZAGF's ROE is +0.06%, compared to DMTK's ROE of -1.39%. Regarding short-term risk, LZAGF is less volatile compared to DMTK. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, AWH has a market cap of 2.89M. Regarding current trading prices, LZAGF is priced at $699.91, while AWH trades at $0.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas AWH's P/E ratio is -0.09. In terms of profitability, LZAGF's ROE is +0.06%, compared to AWH's ROE of +5.16%. Regarding short-term risk, LZAGF is less volatile compared to AWH. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, ISPC has a market cap of 2.86M. Regarding current trading prices, LZAGF is priced at $699.91, while ISPC trades at $1.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas ISPC's P/E ratio is -0.07. In terms of profitability, LZAGF's ROE is +0.06%, compared to ISPC's ROE of -2.39%. Regarding short-term risk, LZAGF is less volatile compared to ISPC. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, IDTA has a market cap of 2.83M. Regarding current trading prices, LZAGF is priced at $699.91, while IDTA trades at $0.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas IDTA's P/E ratio is 6.99. In terms of profitability, LZAGF's ROE is +0.06%, compared to IDTA's ROE of +0.36%. Regarding short-term risk, LZAGF is more volatile compared to IDTA. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, AVCRF has a market cap of 2.83M. Regarding current trading prices, LZAGF is priced at $699.91, while AVCRF trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas AVCRF's P/E ratio is -2.79. In terms of profitability, LZAGF's ROE is +0.06%, compared to AVCRF's ROE of +0.05%. Regarding short-term risk, LZAGF is less volatile compared to AVCRF. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, SQL has a market cap of 2.51M. Regarding current trading prices, LZAGF is priced at $699.91, while SQL trades at $6.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas SQL's P/E ratio is -0.40. In terms of profitability, LZAGF's ROE is +0.06%, compared to SQL's ROE of -0.67%. Regarding short-term risk, LZAGF is less volatile compared to SQL. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, BNR has a market cap of 2.50M. Regarding current trading prices, LZAGF is priced at $699.91, while BNR trades at $2.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas BNR's P/E ratio is -0.50. In terms of profitability, LZAGF's ROE is +0.06%, compared to BNR's ROE of -0.53%. Regarding short-term risk, LZAGF is less volatile compared to BNR. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, NDRA has a market cap of 1.83M. Regarding current trading prices, LZAGF is priced at $699.91, while NDRA trades at $3.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas NDRA's P/E ratio is -0.06. In terms of profitability, LZAGF's ROE is +0.06%, compared to NDRA's ROE of -2.11%. Regarding short-term risk, LZAGF is less volatile compared to NDRA. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, ICBU has a market cap of 1.64M. Regarding current trading prices, LZAGF is priced at $699.91, while ICBU trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas ICBU's P/E ratio is N/A. In terms of profitability, LZAGF's ROE is +0.06%, compared to ICBU's ROE of +0.70%. Regarding short-term risk, LZAGF is less volatile compared to ICBU. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, IBXXF has a market cap of 1.61M. Regarding current trading prices, LZAGF is priced at $699.91, while IBXXF trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas IBXXF's P/E ratio is -0.27. In terms of profitability, LZAGF's ROE is +0.06%, compared to IBXXF's ROE of +0.55%. Regarding short-term risk, LZAGF is less volatile compared to IBXXF. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, IVRO has a market cap of 1.53M. Regarding current trading prices, LZAGF is priced at $699.91, while IVRO trades at $0.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas IVRO's P/E ratio is -0.84. In terms of profitability, LZAGF's ROE is +0.06%, compared to IVRO's ROE of +0.08%. Regarding short-term risk, LZAGF is less volatile compared to IVRO. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, DIGP has a market cap of 1.09M. Regarding current trading prices, LZAGF is priced at $699.91, while DIGP trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas DIGP's P/E ratio is -1.04. In terms of profitability, LZAGF's ROE is +0.06%, compared to DIGP's ROE of +0.05%. Regarding short-term risk, LZAGF is less volatile compared to DIGP. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, HTGM has a market cap of 1.06M. Regarding current trading prices, LZAGF is priced at $699.91, while HTGM trades at $0.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas HTGM's P/E ratio is -0.03. In terms of profitability, LZAGF's ROE is +0.06%, compared to HTGM's ROE of -2.73%. Regarding short-term risk, LZAGF is more volatile compared to HTGM. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, SCRSF has a market cap of 855366.00. Regarding current trading prices, LZAGF is priced at $699.91, while SCRSF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas SCRSF's P/E ratio is -0.09. In terms of profitability, LZAGF's ROE is +0.06%, compared to SCRSF's ROE of +2.91%. Regarding short-term risk, LZAGF is more volatile compared to SCRSF. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, SQLLW has a market cap of 837087.00. Regarding current trading prices, LZAGF is priced at $699.91, while SQLLW trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas SQLLW's P/E ratio is -0.04. In terms of profitability, LZAGF's ROE is +0.06%, compared to SQLLW's ROE of -19.68%. Regarding short-term risk, LZAGF is more volatile compared to SQLLW. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, RSHN has a market cap of 817464.00. Regarding current trading prices, LZAGF is priced at $699.91, while RSHN trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas RSHN's P/E ratio is N/A. In terms of profitability, LZAGF's ROE is +0.06%, compared to RSHN's ROE of -5.42%. Regarding short-term risk, LZAGF is less volatile compared to RSHN. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, EPGNF has a market cap of 692790.00. Regarding current trading prices, LZAGF is priced at $699.91, while EPGNF trades at $0.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas EPGNF's P/E ratio is -0.04. In terms of profitability, LZAGF's ROE is +0.06%, compared to EPGNF's ROE of -4.14%. Regarding short-term risk, LZAGF is more volatile compared to EPGNF. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, NSTM has a market cap of 468815.00. Regarding current trading prices, LZAGF is priced at $699.91, while NSTM trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas NSTM's P/E ratio is -0.14. In terms of profitability, LZAGF's ROE is +0.06%, compared to NSTM's ROE of +0.87%. Regarding short-term risk, LZAGF is less volatile compared to NSTM. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, BIOC has a market cap of 450786.00. Regarding current trading prices, LZAGF is priced at $699.91, while BIOC trades at $0.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas BIOC's P/E ratio is -0.01. In terms of profitability, LZAGF's ROE is +0.06%, compared to BIOC's ROE of -1.38%. Regarding short-term risk, LZAGF is less volatile compared to BIOC. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, TRIB has a market cap of 428554.00. Regarding current trading prices, LZAGF is priced at $699.91, while TRIB trades at $0.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas TRIB's P/E ratio is -0.34. In terms of profitability, LZAGF's ROE is +0.06%, compared to TRIB's ROE of +0.79%. Regarding short-term risk, LZAGF is less volatile compared to TRIB. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, MBGNF has a market cap of 172578.00. Regarding current trading prices, LZAGF is priced at $699.91, while MBGNF trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas MBGNF's P/E ratio is -1.00. In terms of profitability, LZAGF's ROE is +0.06%, compared to MBGNF's ROE of +0.37%. Regarding short-term risk, LZAGF is more volatile compared to MBGNF. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, NVTAQ has a market cap of 85948.00. Regarding current trading prices, LZAGF is priced at $699.91, while NVTAQ trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas NVTAQ's P/E ratio is -0.00. In terms of profitability, LZAGF's ROE is +0.06%, compared to NVTAQ's ROE of +1.79%. Regarding short-term risk, LZAGF is less volatile compared to NVTAQ. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, ARYC has a market cap of 79348.00. Regarding current trading prices, LZAGF is priced at $699.91, while ARYC trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas ARYC's P/E ratio is N/A. In terms of profitability, LZAGF's ROE is +0.06%, compared to ARYC's ROE of +0.55%. Regarding short-term risk, LZAGF is less volatile compared to ARYC. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, HCLC has a market cap of 73985.00. Regarding current trading prices, LZAGF is priced at $699.91, while HCLC trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas HCLC's P/E ratio is N/A. In terms of profitability, LZAGF's ROE is +0.06%, compared to HCLC's ROE of +0.11%. Regarding short-term risk, LZAGF is more volatile compared to HCLC. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, MEDVF has a market cap of 54038.00. Regarding current trading prices, LZAGF is priced at $699.91, while MEDVF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas MEDVF's P/E ratio is -0.03. In terms of profitability, LZAGF's ROE is +0.06%, compared to MEDVF's ROE of +0.57%. Regarding short-term risk, LZAGF is more volatile compared to MEDVF. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, CHHL has a market cap of 37320.00. Regarding current trading prices, LZAGF is priced at $699.91, while CHHL trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas CHHL's P/E ratio is N/A. In terms of profitability, LZAGF's ROE is +0.06%, compared to CHHL's ROE of N/A. Regarding short-term risk, LZAGF is less volatile compared to CHHL. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, IHTI has a market cap of 32514.00. Regarding current trading prices, LZAGF is priced at $699.91, while IHTI trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas IHTI's P/E ratio is N/A. In terms of profitability, LZAGF's ROE is +0.06%, compared to IHTI's ROE of +0.00%. Regarding short-term risk, LZAGF is less volatile compared to IHTI. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, MEDD has a market cap of 31910.00. Regarding current trading prices, LZAGF is priced at $699.91, while MEDD trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas MEDD's P/E ratio is -0.01. In terms of profitability, LZAGF's ROE is +0.06%, compared to MEDD's ROE of +0.74%. Regarding short-term risk, LZAGF is more volatile compared to MEDD. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, CGNH has a market cap of 24046.00. Regarding current trading prices, LZAGF is priced at $699.91, while CGNH trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas CGNH's P/E ratio is N/A. In terms of profitability, LZAGF's ROE is +0.06%, compared to CGNH's ROE of +1.41%. Regarding short-term risk, LZAGF is less volatile compared to CGNH. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, TOMDF has a market cap of 14081.00. Regarding current trading prices, LZAGF is priced at $699.91, while TOMDF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas TOMDF's P/E ratio is N/A. In terms of profitability, LZAGF's ROE is +0.06%, compared to TOMDF's ROE of +0.84%. Regarding short-term risk, LZAGF is less volatile compared to TOMDF. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, ABMC has a market cap of 4810.00. Regarding current trading prices, LZAGF is priced at $699.91, while ABMC trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas ABMC's P/E ratio is 0.01. In terms of profitability, LZAGF's ROE is +0.06%, compared to ABMC's ROE of +0.86%. Regarding short-term risk, LZAGF is more volatile compared to ABMC. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, RGDXQ has a market cap of 3880.00. Regarding current trading prices, LZAGF is priced at $699.91, while RGDXQ trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas RGDXQ's P/E ratio is N/A. In terms of profitability, LZAGF's ROE is +0.06%, compared to RGDXQ's ROE of -1.27%. Regarding short-term risk, LZAGF is less volatile compared to RGDXQ. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, DMTKQ has a market cap of 3525.00. Regarding current trading prices, LZAGF is priced at $699.91, while DMTKQ trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas DMTKQ's P/E ratio is N/A. In terms of profitability, LZAGF's ROE is +0.06%, compared to DMTKQ's ROE of -0.80%. Regarding short-term risk, LZAGF is less volatile compared to DMTKQ. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, GWHP has a market cap of 1313.00. Regarding current trading prices, LZAGF is priced at $699.91, while GWHP trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas GWHP's P/E ratio is -0.00. In terms of profitability, LZAGF's ROE is +0.06%, compared to GWHP's ROE of +0.00%. Regarding short-term risk, LZAGF is less volatile compared to GWHP. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, CYPS has a market cap of 811.00. Regarding current trading prices, LZAGF is priced at $699.91, while CYPS trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas CYPS's P/E ratio is N/A. In terms of profitability, LZAGF's ROE is +0.06%, compared to CYPS's ROE of N/A. Regarding short-term risk, LZAGF is less volatile compared to CYPS. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, ROSGQ has a market cap of 593.00. Regarding current trading prices, LZAGF is priced at $699.91, while ROSGQ trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas ROSGQ's P/E ratio is N/A. In terms of profitability, LZAGF's ROE is +0.06%, compared to ROSGQ's ROE of N/A. Regarding short-term risk, LZAGF is more volatile compared to ROSGQ. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, BIOCQ has a market cap of 263.00. Regarding current trading prices, LZAGF is priced at $699.91, while BIOCQ trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas BIOCQ's P/E ratio is -0.00. In terms of profitability, LZAGF's ROE is +0.06%, compared to BIOCQ's ROE of -1.38%. Regarding short-term risk, LZAGF is more volatile compared to BIOCQ. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, HTGMQ has a market cap of 221.00. Regarding current trading prices, LZAGF is priced at $699.91, while HTGMQ trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas HTGMQ's P/E ratio is N/A. In terms of profitability, LZAGF's ROE is +0.06%, compared to HTGMQ's ROE of -2.73%. Regarding short-term risk, LZAGF is more volatile compared to HTGMQ. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, OPGX has a market cap of 17.00. Regarding current trading prices, LZAGF is priced at $699.91, while OPGX trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas OPGX's P/E ratio is N/A. In terms of profitability, LZAGF's ROE is +0.06%, compared to OPGX's ROE of +0.46%. Regarding short-term risk, LZAGF is more volatile compared to OPGX. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, AGHC comparison data is unavailable. Regarding current trading prices, LZAGF is priced at $699.91, while AGHC trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas AGHC's P/E ratio is N/A. In terms of profitability, LZAGF's ROE is +0.06%, compared to AGHC's ROE of +2.90%. Regarding short-term risk, LZAGF is more volatile compared to AGHC. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, EPGNY comparison data is unavailable. Regarding current trading prices, LZAGF is priced at $699.91, while EPGNY trades at $2.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas EPGNY's P/E ratio is -1.60. In terms of profitability, LZAGF's ROE is +0.06%, compared to EPGNY's ROE of -0.19%. Regarding short-term risk, LZAGF is more volatile compared to EPGNY. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, OCDX comparison data is unavailable. Regarding current trading prices, LZAGF is priced at $699.91, while OCDX trades at $17.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas OCDX's P/E ratio is -42.28. In terms of profitability, LZAGF's ROE is +0.06%, compared to OCDX's ROE of +0.18%. Regarding short-term risk, LZAGF is more volatile compared to OCDX. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, DHR-PA comparison data is unavailable. Regarding current trading prices, LZAGF is priced at $699.91, while DHR-PA trades at $1,841.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas DHR-PA's P/E ratio is 233.57. In terms of profitability, LZAGF's ROE is +0.06%, compared to DHR-PA's ROE of +0.07%. Regarding short-term risk, LZAGF is more volatile compared to DHR-PA. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, BGNX comparison data is unavailable. Regarding current trading prices, LZAGF is priced at $699.91, while BGNX trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas BGNX's P/E ratio is N/A. In terms of profitability, LZAGF's ROE is +0.06%, compared to BGNX's ROE of N/A. Regarding short-term risk, LZAGF is more volatile compared to BGNX. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, MRPS comparison data is unavailable. Regarding current trading prices, LZAGF is priced at $699.91, while MRPS trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas MRPS's P/E ratio is N/A. In terms of profitability, LZAGF's ROE is +0.06%, compared to MRPS's ROE of N/A. Regarding short-term risk, LZAGF is more volatile compared to MRPS. This indicates potentially higher risk in terms of short-term price fluctuations for LZAGF.

LZAGF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LZAGF stands at 49.22B. In comparison, MEUSW comparison data is unavailable. Regarding current trading prices, LZAGF is priced at $699.91, while MEUSW trades at $1.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LZAGF currently has a P/E ratio of 64.57, whereas MEUSW's P/E ratio is N/A. In terms of profitability, LZAGF's ROE is +0.06%, compared to MEUSW's ROE of -3.04%. Regarding short-term risk, LZAGF is less volatile compared to MEUSW. This indicates potentially lower risk in terms of short-term price fluctuations for LZAGF.